arrow_back Back to App

Streamlining Islet Cell Transplants: Regulating Cells as Organs, Not Drugs.

This Act aims to improve access to life-saving islet cell transplants, primarily benefiting individuals with Type 1 diabetes. It reclassifies human cadaveric islets as organs for regulatory purposes, rather than treating them as drugs or biological products. This change is intended to simplify the regulatory process, potentially increasing the availability and speed of these critical transplant procedures.
Key points
Human cadaveric islets will be regulated as organs, simplifying complex medical and distribution procedures.
The change explicitly excludes islets from definitions of 'drug,' 'biological product,' and 'HCT/Ps' under federal law.
This regulatory simplification is expected to increase the availability of transplants for patients with Type 1 diabetes.
The Department of Health and Human Services must update all relevant federal regulations within one year.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_S_3105
Sponsor: Sen. Lee, Mike [R-UT]
Process start date: 2025-11-05